Cancer drug vorasidenib put to the test: will it clash with common meds?

NCT ID NCT07235748

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study in 28 healthy adults checks whether the experimental cancer drug vorasidenib changes how the body processes several common medications, including pain relievers, sedatives, and cholesterol drugs. Participants take the other drugs alone and then again with vorasidenib to compare levels in the blood. The goal is to identify potential drug interactions before vorasidenib is used more widely.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

vorasidenib

What this could lead to

If successful, this study will help doctors understand how vorasidenib interacts with other medications, leading to safer dosing guidelines for patients.

What could go wrong

This is an early-phase study in healthy volunteers, not patients. The results may not fully predict effects in people with illness, and drug interactions can still vary.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY ADULT PARTICIPANTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Celerion

    Belfast, BT9 6AD, United Kingdom